US SEC Filings Daily Market Digest — March 17, 2026

17-03-2026

Carlisle Companies Incorporated's DEF 14A proxy statement, filed March 17, 2026, provides pay versus performance disclosures via XBRL tags for fiscal years 2021-2025, covering the Principal Executive Officer (PEO) and Non-PEO Named Executive Officers (NEOs), including adjustments for equity awards, pension values, and fair value changes. The filing details the non-employee director compensation program, comprising annual retainers (partly in shares), committee leadership fees, restricted share grants, and a deferred compensation plan, with benchmarking conducted in April 2024 by Willis Towers Watson confirming market competitiveness. It also outlines board communication protocols addressed to Mr. Frias (Lead Independent Director) and a strict director retirement policy requiring resignation at age 72 or after 18 years of service.

• ·Employee directors receive no additional compensation for board service.
• ·Corporate Governance and Nominating Committee reviews director pay at least every two years.
• ·Communications to directors screened to exclude commercial, irrelevant, or improper topics.
• ·Board address: 16430 North Scottsdale Road, Suite 400, Scottsdale, Arizona 85254, Attention: Secretary.

17-03-2026

Cortigent, Inc. (CRGT), a spin-off from Vivani Medical, Inc., is filing Amendment No. 17 to its S-1 for a firm commitment IPO of 1,500,000 shares of common stock at an anticipated $10.00 per share, with an underwriter option for 225,000 additional shares; post-IPO, Vivani will own approximately 77% of voting power, making Cortigent a controlled company. The company develops investigational brain implant devices including the Orion Visual Prosthesis (targeting $4B US TAM for 82,000 profoundly blind Americans) and Stroke Recovery System ($6B annual US TAM amid 610,000 annual strokes), building on the discontinued Argus II system. As an emerging growth company with no established public market and high investment risks, including FDA approval uncertainties for its products, the offering highlights promising markets but pre-commercial status.

• ·Argus II sales discontinued in 2019 to refocus on Orion
• ·Orion completed 6-year Early Feasibility Study in March 2025 with FDA Breakthrough Device designation
• ·Applied for NYSE American listing under symbol CRGT; offering will not proceed without approval
• ·Emerging growth company and smaller reporting company status
• ·Investigational devices (Orion and Stroke Recovery) require FDA approval; no assurance of success

17-03-2026

On March 15, 2026, Sean Smith resigned as Chief Accounting Officer of QXO, Inc., effective immediately, to pursue employment closer to his family, and agreed to serve in an advisory role until June 30, 2026, with continued compensation including prorated salary, bonus, and equity vesting. The departure is not due to any disagreements on accounting principles, financial statements, or internal controls. On March 16, 2026, Robert Loughran was appointed as Interim Chief Accounting Officer, effective immediately, while the company searches for a permanent successor.

• ·No family relationships between Mr. Loughran and any directors or executive officers.
• ·No arrangements or understandings pursuant to which Mr. Loughran was selected as an officer.
• ·No material transactions involving Mr. Loughran subject to Item 404(a) of Regulation S-K.
• ·Mr. Loughran's prior roles: Partner at Elm Street Advisors (since 2023), CFO at Greenidge Generation Holdings (Jan 2022-Oct 2023), CAO at Greenidge (Jun 2021-Jan 2022), VP Corporate Controller at Tronox Holdings PLC (Apr 2018-Jun 2020), various senior roles at Avon including Group VP CAO (Mar 2016-Mar 2019) and VP Corporate Controller (May 2012-Mar 2016).
• ·Mr. Loughran is a Certified Public Accountant with a BS from University of Connecticut.

17-03-2026

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102 showing 85% CRP reductions in elevated CVD-risk subjects and unblinded safety data with no SAEs across 88 participants, alongside 100% PSA response rate for MRT-2359 in combination with enzalutamide in mCRPC patients with AR mutations; the company raised $345M in an upsized follow-on offering, extending cash runway into 2029. However, Q4 2025 collaboration revenue fell sharply 95% YoY to $2.8M from $60.6M, R&D expenses rose 8% YoY to $42.0M, and net loss widened to $46.1M from $13.4M, despite full-year net loss improving to $38.6M from $72.7M.

• ·No SAEs or >Grade 2 AEs in MRT-8102 SAD/MAD; treatment-emergent AEs 22% vs 32% placebo.
• ·NOAEL at highest dose tested (200-300x projected human dose) in 3-month cyno tox study.
• ·Novartis eligible to trigger up to $2.1B milestones for MRT-6160 starting Phase 2; second collab up to $5.7B total value.
• ·Phase 2 initiations: MRT-8102 GFORCE-2 H2 2026, GFORCE-3 Q4 2026/Q1 2027, GFORCE-4 H1 2027; MRT-2359 MODeFIRe-1 Q3 2026; Novartis MRT-6160 multiple Phase 2 in 2026.
• ·IND submissions planned 2026 for second-gen NEK7 MGD and cyclin E1-directed MGD.

17-03-2026

Citi Trends reported strong Q4 FY2025 results with total sales of $230.4M, up 9.1% YoY from $211.2M and comparable store sales growth of 8.9% (two-year stack 15.3%), alongside FY2025 sales of $820.0M, up 8.9% YoY from $753.1M with 9.7% comps growth (two-year 13.1%). Gross margins expanded 20bps to 39.9% in Q4 and 210bps to 39.6% FY, driving net income of $7.4M in Q4 (vs. $14.2M loss) and $5.2M FY (vs. $43.2M loss), with adjusted EBITDA of $11.9M Q4 (vs. $7.1M) and $11.8M FY (vs. -$14.2M, +$26M). However, SG&A expenses increased nominally to $80.0M in Q4 (vs. $77.5M) and $313.2M FY (vs. $300.2M) due to higher sales volume and incentive compensation, though leveraged 160bps and 120bps respectively on a rate basis.

• ·Opened 3 new stores, remodeled 62 locations, and closed 4 stores in FY2025.
• ·No debt and no borrowings under $75M credit facility.
• ·Q1 FY2026 quarter-to-date comparable store sales trending high-single digits.
• ·FY2026 outlook: total sales growth 6-8%, comps 5-7%, gross margin +100bps, adjusted EBITDA $34M-$38M, capex $35M-$40M, open ~25 stores, remodel 50, close 4.
• ·Equity-based compensation FY2025 totaled $5.4M; expected $5.5M-$6.0M in FY2026.

17-03-2026

Marten Transport, Ltd. (MRTN) filed its definitive DEF 14A proxy statement on March 17, 2026, for the 2026 Annual Meeting of Stockholders on May 5, 2026, proposing the election of seven incumbent directors, an advisory vote to approve executive compensation, and ratification of Grant Thornton LLP as independent auditors for 2026. The record date is March 6, 2026, with 81,589,135 shares of common stock outstanding, requiring a quorum of 40,794,568 shares. Voting details specify majority-of-votes-cast for all proposals, with brokers able to vote on auditor ratification but not on director election or say-on-pay.

• ·Annual Meeting location: Roger Marten Community Center, 120 South Franklin Street, Mondovi, Wisconsin at 2:00 p.m. local time.
• ·Proxy materials expected to be mailed on or about March 17, 2026.
• ·All seven director nominees are current board members, each elected at the prior year's annual meeting.
• ·Broker non-votes have no effect on Proposals 1 and 2 but are not expected on Proposal 3 (routine matter).
• ·Ages of nominees as of February 13, 2026; director service start dates range from 1980 (Randolph L. Marten) to 2023 (Patricia L. Jones).

17-03-2026

Tri Pointe Homes, Inc. entered into a Merger Agreement dated February 13, 2026, with Sumitomo Forestry Co., Ltd. and its indirect wholly-owned subsidiary Teton NewCo, Inc., under which Merger Sub will merge with and into the Company, making it an indirect subsidiary of Parent. A Special Meeting of stockholders is scheduled for April 16, 2026, at 10:00 a.m. PT in Irvine, CA, to vote on the Merger Agreement Proposal (requiring majority approval of outstanding shares), a non-binding advisory Compensation Proposal for named executive officers, and an Adjournment Proposal if needed; the Record Date is March 16, 2026, with 85,135,563 shares outstanding. The Board unanimously recommends voting FOR all proposals.

• ·Quorum at Special Meeting requires presence (in person or proxy) of holders of a majority of outstanding shares.
• ·Merger Agreement Proposal requires affirmative vote of majority of outstanding shares; failure to vote (if quorum present) has same effect as vote AGAINST.
• ·Proxy materials to be mailed on or about March 17, 2026; available online at https://investors.tripointehomes.com/investors/financial-info/sec-reports/.
• ·Proxy solicitor: D.F. King & Co., Inc. (contact details provided).

17-03-2026

Vesicor Therapeutics, Inc., an early-stage biotech and proposed de-SPAC acquisition target for Black Hawk Acquisition Corp (Nasdaq: BKHA, BKHAU, BKHAR), appointed Michael Tolentino, M.D., as CEO effective March 17, 2026, succeeding founder Luo Feng, Ph.D., who transitions to Chief Scientific Officer. Tolentino brings over 20 years of biotech experience, including inventing contributions to Avastin, founding Acuity Pharmaceuticals (merged into OPKO Health), scientific founding Promedior (sold to Roche), and co-founding Aviceda Therapeutics (raised $207.5M Series C) and Avdarna Therapeutics. The company plans to accelerate IND-enabling studies toward a 2027 FDA IND submission, though it notes standard forward-looking risks including lack of current FDA approval and funding needs.

• ·Vesicor has not commenced FDA regulatory approval process for its sole product candidate as of March 17, 2026
• ·Tolentino co-founded Aviceda Therapeutics and served as CSO (2018-2021), CTO/CIO (2018-2025), and board member (2018-2024)
• ·Aikium's Yotta-ML platform targets GLP-1, GIP-1, glucagon agonists, checkpoint inhibitors, and cancer antigens for microvesicle conjugation

17-03-2026

Dragonfly Energy reported preliminary full year 2025 net sales of $58.6 million, up 15.8% YoY driven by 33.8% growth in OEM sales to $36.9 million, though DTC sales declined 8.5% to $20.7 million amid RV market softness. Q4 net sales increased 6.9% to $13.1 million with OEM up 30.1% to $8.1 million, but gross margin contracted to 18.2% from 20.8% and net loss widened to $45.0 million from $9.8 million. The company implemented a strategic cost realignment for $8.9 million in annualized savings and targets positive Adjusted EBITDA at a $70 million annual revenue run rate, while guiding Q1 2026 net sales at $9.5 million and Adjusted EBITDA loss of $4.6 million.

• ·Targets positive Adjusted EBITDA at $70M annual revenue run rate.
• ·Executive and Board cash compensation reduced 20% for remainder of FY2026, replaced with equity incentives.
• ·20% reduction in total payroll expense via workforce reductions and salary adjustments.
• ·Preliminary results subject to audit and potential material adjustments.
• ·Conference call held March 16, 2026 at 4:30 PM ET.

17-03-2026

BioCardia, Inc. announced on March 17, 2026, that the FDA has accepted its pre-submission package for approval of the Helix Transendocardial Delivery Catheter, intended for intramyocardial therapeutic and diagnostic agent delivery. This regulatory milestone advances the product's development pathway. No financial or performance metrics were disclosed.

• ·Filing includes Exhibit 99.1: BioCardia press release dated March 17, 2026
• ·Information furnished under Item 8.01, not deemed 'filed' under Section 18 of the Exchange Act

17-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) issued a press release on March 17, 2026, announcing that its RAD division received an order for 10 RIO Mini units with SARA licenses from a major Midwest construction company. No financial terms or order value were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated March 17, 2026.

17-03-2026

A Paradise Acquisition Corp., a SPAC, is merging with Enhanced, an innovative sports company launching the Enhanced Games that permit FDA-approved performance-enhancing substances under medical supervision to prioritize athlete health, safety, and higher compensation compared to traditional athletics. CEO Max Martin discusses overcoming PED stigma, the Enhanced Games Medical Program run as a clinical study in Abu Dhabi with SSMC Hospital, and benefits for both elite and returning athletes. Accelerate Arbitrage Fund discloses a long position in A Paradise Acquisition shares and rights.

• ·Enhanced Games idea originated roughly 2.5 years ago.
• ·Athletes receive comprehensive baseline assessments and continuous medical screenings as part of the Medical Program.
• ·Focus on two athlete types: prime athletes aiming to break records and older athletes (e.g., mid-30s) seeking personal bests.

17-03-2026

ProCap Financial, Inc. (BRRWW) filed a DEFA14A Additional Proxy Statement on March 17, 2026. The provided content consists solely of standard forward-looking statement disclaimers, legal notices regarding securities offerings, and contact information for media and investors. No financial metrics, period-over-period comparisons, or material business updates are included.

17-03-2026

Mechanics Bancorp reported net income of $266M in 2025, up 817% YoY from $29M, boosted by a $145M bargain purchase gain from the September 2, 2025 merger with HomeStreet Bank and noninterest income swing to $223M from a $139M loss. Net interest income grew 13% YoY to $586M with NIM expanding 12 bps to 3.43%, while total assets expanded 36% to $22.4B and deposits rose 36% to $19.0B. However, provision for credit losses on loans increased to $20.5M from a $1.6M reversal, nonaccrual loans tripled to $43M (0.30% of total loans), and noninterest expenses rose 36% to $470M driven by $73M acquisition/integration costs.

• ·Common equity Tier 1 capital ratio for Mechanics Bancorp: 14.09% (newly reported post-merger)
• ·Tangible common equity ratio declined to 8.48% from 9.10%
• ·Loans to deposits ratio increased to 74.52% from 69.17%
• ·Full time equivalent employees grew 34% to 1,921

17-03-2026

Eureka Acquisition Corp, a SPAC, issued an interest-free $150,000 Extension Promissory Note to Marine Thinking Inc. on March 13, 2026, payable upon consummation of a business combination or the SPAC's term expiry. The note is convertible into private units at $10 per unit if elected prior to closing, with units non-transferable until business combination completion. This supports ongoing merger discussions ahead of a planned Form S-4 registration statement.

• ·Note filed as Exhibit 10.1 in Form 8-K dated March 16, 2026, effective March 17, 2026.
• ·Conversion requires notice at least two business days prior to business combination closing.
• ·Overdue amounts accrue interest at prevailing short-term US Treasury Bill rate.
• ·Annual Report on Form 10-K filed December 15, 2025.

17-03-2026

Pelican Acquisition Corp disclosed under Item 7.01 three promotional discussions on March 13, 14, and 16, 2026, featuring Greenland Energy Company's CEO Robert Price and incoming director Larry G. Swets, Jr., regarding the pending Business Combination with Greenland Exploration Limited, March GL, and PubCo. The filing furnishes transcripts as Exhibits 99.1 and 99.2 and references a Registration Statement on Form S-4 declared effective on February 17, 2026. It emphasizes forward-looking statements with extensive risk factors, including potential delays, redemptions, and failure to complete the merger.

• ·Registration Statement on Form S-4 effective February 17, 2026.
• ·Pelican 10-Q filings: July 31, 2025 (filed September 15, 2025), April 30, 2025 (filed June 27, 2025).
• ·S-1 effective May 22, 2025.

17-03-2026

Cineverse Corp. filed a Form S-3 shelf registration statement on March 16, 2026, to register up to 21,805,701 shares of Class A Common Stock for resale by selling stockholders from time to time on Nasdaq or otherwise. The company will not receive any proceeds from these sales but has agreed to pay certain registration expenses to satisfy registration rights granted to the selling stockholders. The Common Stock (CNVS) had a last reported sale price of $2.60 per share on March 13, 2026.

• ·Registrant classified as non-accelerated filer and smaller reporting company.
• ·Incorporated in Delaware with I.R.S. Employer Identification Number 22-3720962.
• ·Principal executive offices at 224 W. 35th St., Suite 500, #947, New York, New York 10001.
• ·Par value of Common Stock: $0.001 per share.

17-03-2026

For the six months ended January 31, 2026, PURE BIOSCIENCE, INC. reported revenue growth of 21.7% YoY to $1.152M, driven by strong performance in PURE Hard Surface (+46.8% to $1.136M for the month), while SILVÉRION revenue declined sharply 91.9% to $14,000. Net loss narrowed 16.0% YoY to $1.249M amid lower G&A expenses, however interest expense rose to $195,000 from $132,000 and dilutive securities outstanding surged 63.3% to 68.6M shares. Convertible notes increased to $5.52M principal plus $625,000 accrued interest.

• ·Fiscal 2026 Notes issued totaling $720K at 6.34%-6.68% interest, maturing Oct-Dec 2028.
• ·G&A expenses decreased 10.2% YoY to $1.498M for six months.
• ·Interest expense increased 47.7% YoY to $195K for six months.

17-03-2026

Unknown Company filed its 10-K annual report on March 17, 2026, including detailed assessments of compliance with Regulation AB Item 1122 servicing criteria for asset-backed securities by servicers Midland, PBLS, and KeyBank. Applicable criteria are predominantly performed directly by these servicers or by vendors for which they are responsible, while many others are marked as not applicable or not performed by them. No material non-compliance, exceptions, or performance issues are disclosed across the tables.

• ·Multiple criteria reference standard timeframes such as deposits/postings within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days.
• ·N/A notations appear frequently for criteria like back-up servicer maintenance (1122(d)(1)(iii)), investor remittances (1122(d)(3)(ii)-(iv)), and external enhancements (1122(d)(4)(xv)).

17-03-2026

American Rebel Holdings Inc entered into a Securities Purchase Agreement issuing a promissory note to 1800 Diagonal Lending LLC with a principal amount of $124,200 purchased for $108,000 (including $16,200 OID), requiring total repayments of $147,487 over 15 monthly installments from April 15, 2026 to June 15, 2027 at an effective 15% interest rate. The note includes high default interest of 22%, acceleration to 150% of outstanding amounts upon events of default, and conversion rights into common stock (limited to 4.99% beneficial ownership, subject to Nasdaq 19.99% rule without stockholder approval), posing dilution risk. Prepayment is permitted at 95% of principal plus interest within the first 180 days without penalty.

• ·5-day grace period for payments; missed payment triggers Event of Default.
• ·Covenant restricts sale of significant assets without Holder consent to avoid shell company status.
• ·Events of Default include failure to pay (after 5 business days notice), covenant breaches (after 20 days notice), bankruptcy, delisting from Exchanges, non-compliance with Exchange Act reporting.
• ·Conversion rights exercisable only after Event of Default; Notice of Conversion must be before 6pm NY time.
• ·Prepayment requires 3 Trading Days prior notice; no partial prepayments except as specified.

17-03-2026

Brookfield Infrastructure Partners L.P. reported strong FY2025 financials with revenues up 9.8% YoY to $23.1B, FFO up 6.4% to $2.6B, and net income attributable to the partnership surging 179% to $1.1B, driven by higher other income. However, mark-to-market losses widened to $548M from $26M, and in the Utilities segment, while total Adjusted EBITDA grew 6.1% to $1.3B, Regulated Transmission EBITDA was essentially flat at $552M (up 0.9%) after declining from $631M in 2023. The year featured active portfolio management with acquisitions totaling over $2B (e.g., HomeServe for $1.2B) and divestitures generating ~$1.5B in net proceeds.

• ·Total assets grew 22.5% to $128.2B as of Dec 31, 2025.
• ·Non-recourse borrowings increased to $59.6B from $46.6B.
• ·FFO payout ratio stable at 66% in 2025 vs 67% in 2024.
• ·Agreed sale of Mantiqueira expected to close H1 2026 for $150M.

17-03-2026

Brookfield Infrastructure Corp's annual report for year ended December 31, 2025, reports cash from operating activities declining 8% YoY to $1,608M from $1,743M, while cash used in investing activities improved significantly with a reduced outflow of $612M from $1,110M. Cash used in financing activities worsened to $1,291M outflow from $428M. Non-recourse borrowings totaled $13.5B with projected interest expense of $4.95B, and base management fees grew 6% YoY to $71M.

• ·Exchangeable shares increased slightly to 132,994,956 as of Dec 31, 2025 from 132,051,909 in 2024 (+0.7%).
• ·USD stock highs in Q4 2025 reached $36.41, comparable to $36.42 in Q4 2024, with trading volume increasing to 36.2M units from 21.9M.

17-03-2026

Ethos Technologies Inc. reported revenue of $387.6M for FY 2025, up 52% YoY from $254.9M, driven by strong growth in DTC channel revenue (+40% to $242.5M) and third-party channel revenue (+79% to $145.1M). Gross profit rose 53% to $380.9M with margin expansion to 98% from 97%, and Adjusted EBITDA increased 55% to $89.0M with flat 23% margin; however, net income margin slightly declined to 18% from 19%, sales and marketing expenses surged 54% to $229.3M (59% of revenue), and G&A expenses jumped 77% to $39.6M (10% of revenue).

• ·Contribution profit FY 2025: $162.0M (42% margin) vs FY 2024: $104.6M (41% margin)
• ·Cost of revenue FY 2025: $6.7M vs FY 2024: $6.5M
• ·Depreciation and amortization FY 2025: $5.4M (flat YoY)
• ·Income tax expense FY 2025: $4.6M vs FY 2024: $5.1M

17-03-2026

Two Harbors Investment Corp. adjourned its Special Meeting of Stockholders to March 24, 2026, at 11:00 a.m. ET to solicit additional proxies in favor of its proposed acquisition by UWM Holdings Corporation. The Board unanimously recommends voting 'FOR' the Merger Proposal, Non-Binding Compensation Advisory Proposal, and Adjournment Proposal, as detailed in the proxy statement dated February 9, 2026. While the Board views the transaction as in stockholders' best interest, the communication emphasizes significant risks and uncertainties, including potential failure to obtain approvals, integration challenges, and adverse market effects.

• ·Proxy statement/prospectus declared effective by SEC on February 9, 2026; mailing commenced on or about February 12, 2026.
• ·Assistance for voting available via D.F. King toll-free at (888) 887-0082.
• ·Two Harbors 10-K for FY ended December 31, 2025 filed February 17, 2026; UWM 10-K filed February 25, 2026.

17-03-2026

Tenon Medical, Inc. closed a private placement of senior convertible promissory notes with institutional and high net worth investors for gross proceeds of $4.3 million before placement agent fees. The notes have a 20% original issue discount, aggregate principal of $4.3 million, mature on September 11, 2026, and are convertible into common stock after a six-month anniversary at 80% of the VWAP for the prior three trading days. Net proceeds will support commercial expansion, product development, clinical studies, working capital, and general corporate purposes.

• ·Notes not registered under Securities Act of 1933; may not be offered or sold absent registration or exemption
• ·WallachBeth Capital, Inc. acted as placement agent
• ·National launch of Catamaran SI Joint Fusion System in October 2022
• ·Company formed in 2012

17-03-2026

McEwen Inc. reported full-year 2025 revenue of $197.6 million, up 13% YoY from $174.5 million in 2024, driven by a 48% higher average realized price of $3,532 per GEO despite a 22% decline in GEO sales from 100% owned operations to 58,552. Consolidated GEO sales fell 16% to 113,732, including an 9% drop in attributable GEOs from the San José mine to 55,180. Additionally, on February 6, 2026, McEwen Copper secured a loan facility of up to $240 million, with $28.5 million drawn to date at 12% annual interest, to fund the Los Azules Project and other purposes.

• ·Loan proceeds for McEwen Copper to be used for general corporate purposes, working capital, going public transaction costs, and advancing Los Azules Project toward Final Investment Decision.
• ·Company received 203,280 transferable warrants to purchase McEwen Copper shares at $40 per share as part of loan agreement.
• ·Argentina corporate income tax rate changed to progressive 25%-35% for fiscal years starting on/after Jan 1, 2021, with annual inflation adjustments from Jan 2022.

17-03-2026

Hammer Technology Holdings Corp. reported a reduced net loss from continuing operations of $153K for the three months ended January 31, 2026, compared to a $280K loss in the prior year period, driven by lower operating expenses ($139K vs. $348K). Cash and equivalents increased to $28K from $18K at July 31, 2025, supported by $339K in related-party financing, however total assets declined 22% to $182K amid amortization of intangibles, while total liabilities rose 19% to $1.15M and stockholders' deficit worsened to $(968K). For the six months, operating cash burn improved to $328K from $497K, but the company continues to generate no revenue from continuing operations.

• ·Intangible assets declined to $154K from $216K due to amortization.
• ·Selling, general and administrative expenses for six months ended Jan 31, 2026: $242K (down 33% YoY from $363K).
• ·No revenue reported from continuing operations in any period.
• ·Gain on disposal of subsidiaries in prior year discontinued operations: $1.66M for three and six months ended Jan 31, 2025.

17-03-2026

BW Industrial Holdings Inc., a Delaware-based general building contractor for nonresidential buildings, filed Amendment No. 2 to its S-1 registration statement on March 17, 2026, for an IPO of 2,625,000 shares of common stock on NYSE American under symbol BWGC, with an anticipated price range of $6-$7 per share (midpoint $6.50), targeting gross proceeds of $17.1M. Net proceeds to the company before expenses are estimated at $16.0M after 6% underwriting discounts of $1.0M to lead underwriter Eddid Securities USA Inc., with a 45-day over-allotment option for up to 393,750 additional shares potentially increasing totals to $19.6M gross and $18.4M net. Post-IPO, CEO and Director Yunlong Zhang will retain control with approximately 57.21% voting power, qualifying the company as a 'controlled company' and emerging growth company.

• ·Company address: 2825 Wilcrest Drive, Suite 421, Houston, TX 77042.
• ·I.R.S. Employer Identification No.: 33-4856491.
• ·Standard Industrial Classification Code: 1541 (General Building Contractors - Nonresidential Buildings).
• ·SEC File Number: 333-292504.
• ·Emerging growth company electing reduced reporting requirements under JOBS Act.